In fact, for many aggressive hematological cancers, including CLL, DLBCL, T-ALL, and NKTL, CD38 expression is significantly associated with poorer prognosis and a hyperproliferative or metastatic phenotype. This evidence concerns the gene SCYL1 and hematopoietic and lymphoid cell neoplasm.